TIGIT and neoplasm: Similarly, ZGGS15, an IgG4 BsAb targeting LAG-3 and TIGIT, demonstrated potent anti-tumor efficacy without inducing ADCC, suggesting a safer and more effective approach (Dai et al., 2024).